Biogen (MEX:BIIB) Research & Development: MXN34,404 Mil (TTM As of Mar. 2026)


MEX:BIIB Biogen Inc MEX:BIIB
59 GF Score
Price MXN3,335.50
GF Value MXN3,205.98
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Biogen Research & Development?

Biogen MEX:BIIB 59 Research & Development is MXN34,404 Mil as of Mar. 2026. GuruFocus rates MEX:BIIB with a GF Score™ of 59/100 and a GF Value™ of MXN3,205.98 (Fairly Valued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Biogen's Research & Development for the three months ended in Mar. 2026 was MXN9,720 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN34,404 Mil.

Biogen  (MEX:BIIB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Biogen Research & Development Related Terms

Biogen Research & Development Historical Data

* Premium members only.

The historical data trend for Biogen's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Research & Development Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51,309.62 43,497.53 41,508.83 41,300.54 32,024.94

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,880.91 7,512.85 7,999.91 9,172.10 9,719.63
MEX:BIIB
59GF Score
Biogen Inc MEX:BIIB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN34,404 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN34,404 Mil mean?
Biogen (MEX:BIIB) has a Research & Development of MXN34,404 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Biogen and its competitors.
Is Biogen's Research & Development too high?
Biogen's current Research & Development is MXN34,404 Mil. Overall, Biogen has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Research & Development compare to OGN and AMRN?
Biogen's Research & Development of MXN34,404 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Biogen and its competitors. Biogen's current Research & Development is MXN34,404 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (MEX:BIIB) is currently considered Fairly Valued. The stock's GF Value™ is MXN3,205.98, compared to a current price of MXN3,335.50 — trading 4% above its estimated fair value. The current Research & Development is MXN34,404 Mil. Biogen's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Biogen (MEX:BIIB), the current Research & Development is MXN34,404 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (MEX:BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of MXN3,335.50 is trading 4% above its estimated GF Value™ of MXN3,205.98. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for MEX:BIIB:

  • Research & Development: MXN34,404 Mil
  • GF Value™: MXN3,205.98 vs. price of MXN3,335.50 (4% above fair value)
  • GF Score™: 59/100 with 7 warning signs

No single metric tells the full story. See the MEX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
59GF Score

Get the complete analysis for MEX:BIIB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,335.50
Price
MXN3,205.98
GF Value